Brief: Neurocrine Biosciences Q4 Adjusted EPS USD 1.69 Vs. IBES Estimate USD 1.56
06/02/2025 21:01
Feb 06 (Reuters) - Neurocrine Biosciences Q4 product sales USD 621.2 million. * Q4 adjusted net income USD 173.4 million vs. IBES estimate USD 158.1 million * Q4 EPS USD 1 * Q4 net income USD 103.1 million
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall